InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,061.34
(
1.01%
)
US TECH 100
16,998.00
(
1.46%
)
Dow Jones
38,427.47
(
0.49%
)
Brent Oil
86.77
(
0.41%
)
Bitcoin
66,478.64
(
-0.57%
)
Post# of 30
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

AugustStockInformer

Send PM Follow Ignore
Followers 2
Posts 34
Boards Moderated 0
Alias Born 06/06/2017

AugustStockInformer

Re: None

Tuesday, 06/06/2017 4:48:15 PM

Tuesday, June 06, 2017 4:48:15 PM

Post# of 30
Genius stock analyst called this one weeks ago, see his other picks:
https://www.twst.com/news/citigroup-nysec-senior-analyst-explains-new-biotech-ecosystem-liquid-biopsy-cancer-genetics-nasdaqcgix-may-lead-personal-genomic-medicine-loxo-oncology-nasdaqloxo/

May 3, 2017
Yigal Nochomovitz, Ph.D. is a Director and Smid-Cap biotech analyst at Citigroup (NYSE:C) Investment Research & Analysis. In a recent interview with the Wall Street Transcript, Dr. Nochomovitz states that “Loxo has a drug for a rare type of cancer, and so it is going to need to engage with companies that are developing next-generation sequencing tests to do more genetic profiling of tumors.” Specifically, according to Loxo Oncology (NASDAQ:LOXO):
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up